Research Paper Volume 15, Issue 1 pp 230—245
Increased expression of GPX4 promotes the tumorigenesis of thyroid cancer by inhibiting ferroptosis and predicts poor clinical outcomes
Figure 4. GPX4 expression and clinicopathological features in thyroid cancer patients. The Wilcoxon rank sum test was applied to analyze associations of clinical T stage (A) and pathologic stage (B) with GPX4 expression. (C) ROC curve analysis evaluating the diagnostic performance of GPX4 in thyroid cancer. (D) Nomogram was built to examine 1-, 3-, and 5-year overall survival based on the risk score model of GPX4 expression. (E) Calibration plot verifying the efficiency of the nomogram for overall survival. (F) Nomogram was built to examine 1-, 3-, and 5-year progression-free interval based on the risk score model of GPX4 expression. (G) Calibration plots verifying the efficiency of the nomogram for progression-free interval.